BioSpace News Archive

35% median reduction in peripheral leukemic blasts achieved with Iomab-B dosimetry dose that is 7 times lower than proposed Iomab-ACT dose

Company’s Antibody Recruiting Molecules (ARMs) Demonstrated Strong Anti-Multiple Myeloma Activity In Multiple In Vivo Animal Models and Ex Vivo Against Patient Tumor Cells

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that abstracts for both fimepinostat and CA-4948 were accepted for presentation at the 61st Annual Meeting of the American Society of Hematology which will be held December 7-10, 2019, in Orlando, FL.

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments

Concert Pharmaceuticals, Inc. announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019.

Backing will propel PAI’s market leadership position and help capitalize on growth opportunities

STAAR Surgical Company announced that the Company will host an Investor and Analyst Day on Friday, November 8, 2019 in New York City at 8:30 a.m. EST.

New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug candidate glenzocimab (ACT017) in acute ischemic stroke

Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent; Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million

LabCorp®, a leading global life sciences company, announced that John Ratliff is departing the company to pursue another opportunity.